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Background: Antibiotic resistance is a major barrier to the continued success of antibiotic treatment. Such
resistance is often generated by overly long durations of antibiotic treatment. A barrier to identifying the
shortest effective treatment duration is the cost of the sequence of clinical trials needed to determine shortest
optimal duration. We propose a new method to identify the optimal treatment duration of an antibiotic
treatment regimen.
Methods: Subjects are randomized to varying treatment durations and the cure proportions of these durations
are linked using a logistic regression model, making effective use of information across all treatment duration
groups. In this paper, Monte Carlo simulation is used to evaluate performance of such a model.
Results: Using a hypothetical dataset, the logistic regression model is seen to provide increased precision in
defining the point estimate and confidence interval (CI) of the cure proportion at each treatment duration.
When applied to the determination of non-inferiority, the regression model allows identification of the shortest
duration meeting the predefined non-inferiority margin.
Conclusions: This analytic strategy represents a practical way to develop shortened regimens for tuberculosis
and other infectious diseases. Application of this strategy to clinical trials of antibiotic therapy could facilitate
decreased antibiotic usage, reduce cost, minimize toxicity, and decrease the emergence of antibiotic resistance.
Keywords: Antibiotic trials, Antibiotic treatment duration, Tuberculosis, Logistic regressionBackground
Antibiotic therapy for the treatment of infectious dis-
eases transformed the practice of medicine in the twenti-
eth century. However, as that century drew to a close,
antibiotic resistance emerged as a major barrier to the
continued success of antibiotic treatment [1]. Since then,
we have learned that antibiotic resistance has many
predisposing factors, including selective pressure of
non-curative regimens, genetic exchange of resistance
mutations between microbial species and indiscriminate
use of antibiotics for non-bacterial conditions [2].
Identification of antibiotic regimens that minimize the
emergence of resistance is hampered by limited informa-
tion about the optimal duration of antibiotic treatment* Correspondence: rhorsbu@bu.edu
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distribution, and reproduction in any mediumable to cure disease without causing microbial resistance.
While pharmacokinetic parameters are used to identify
antibiotic doses that provide the most advantageous
balance between efficacy and tolerability, few antibiotic
regimens have been subjected to rigorous evaluation
of treatment duration. There are notable exceptions, of
course; the appropriate durations of antibiotic treatment
necessary for urinary tract infections in women and for
sexually transmitted diseases have been well studied [3],
and a large series of trials established the shortest effec-
tive antibiotic treatment regimen for tuberculosis [4].
However, data are lacking for the optimal treatment du-
ration for many other diseases, including diarrhea, me-
ningitis and pneumonia. Moreover, the likely introduction
of new antibiotics for the treatment of tuberculosis in the
coming decade will require re-evaluation of the shortest
optimal tuberculosis treatment duration [5,6].
Since treatment for too short a period of time can lead
to unacceptably high failure proportions, pre-licensuretral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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what longer than the likely minimum. Once an initial ef-
fective therapy has been established, subsequent trials to
assess the effectiveness of shorter durations of the same
regimen, or new regimens to treat the same condition, are
evaluated in equivalence trials designed to show that the
new duration or regimen can achieve a cure proportion
that is within a small ‘margin of inferiority’ of the cure
proportion of the accepted standard regimen [7]. This
means that in order for a new duration or antibiotic to be
approved for use, there must be sufficient evidence that it
is no less effective than the standard regimen by more
than a pre-specified amount. Trials that seek to show
‘non-inferiority’ require, of necessity, large numbers of
subjects (N) because the required width of the 95% confi-
dence interval (CI) around the point estimate is often the
determining factor. Thus, they are very costly.
The result is that there is strong pressure to conduct
studies or trials that evaluate only one treatment du-
ration, since evaluation of multiple durations (d) would
require separate study arms for each time period and a
total of N × d study subjects. To minimize the risk of
failing to demonstrate non-inferiority, a single treatment
duration that is substantially greater than the theoretical
minimum duration required is often selected and these
study results are used to establish treatment guidelines.
The outcome is that the shortest optimal duration of
treatment is almost never identified and we are left in
the unenviable position of prescribing antibiotics for lon-
ger durations than are likely necessary [3]. The downside
of this approach, as clearly identified by Rice [3], is that
every additional day of antibiotic treatment beyond the
minimum required to cure disease increases the risk that
host flora will develop resistance to the antimicrobial
agent, not to mention additional costs to patients and
health providers. Therefore, it behooves us to determine
the minimum duration of antibiotic treatment of any
given infectious disease. An additional incentive to de-
termine the minimum duration of treatment is that for
diseases where the duration is substantial, such as tuber-
culosis, reducing the duration of treatment can substan-
tially reduce cost and increase adherence [8].
In this paper, we propose use of an alternative clinical
trial design to evaluate varying durations of antibiotic
regimens for the treatment of infectious diseases within
a single trial. This trial design should be particularly use-
ful when the standard of treatment is highly effective
and the expected number of treatment failures is small
because non-inferiority designs are usually employed for
these types of studies. The design that we propose does
not reduce the overall sample size necessary to conduct
a trial compared to a non-inferiority trial of a single ex-
perimental regimen, but takes advantage of the relation-
ship between gradually increasing durations to allowidentification of the optimal treatment duration, with
modest increase in sample size compared to the traditional
evaluation of a single treatment arm.
Methods
We describe a trial design to evaluate several treatment
durations simultaneously, thereby facilitating selection of
the treatment duration that best satisfies a set of pre-
specified criteria. While this could be accomplished by
conducting a large clinical trial that includes multiple
trial arms of varying treatment durations where each
arm is sufficiently powered to produce a stable estimate
of the cure proportion for each duration, such an ap-
proach would be cost and time prohibitive. Instead, we
propose using a logistic regression framework to link the
cure proportions from several smaller trial arms of varying
treatment durations in order to make effective use of infor-
mation across all treatment duration groups [9], allowing
for the evaluation of several trial arms of varying treatment
duration without having to power the study for each in-
dividual trial arm.
Our proposed approach utilizes a postulated connection
between increasing durations of treatment and subsequent
increases in the cure proportion. In this paper, we will as-
sume a linear relationship between the log odds of the
cure proportion and the duration of treatment. We believe
this is a reasonable, although approximate, relationship to
assume for antibiotic treatment. While this is a convenient
form for use in logistic regression modeling, other non-
linear relationships could be also considered. The form of
the relationship between duration and the outcome could
vary by the medical condition and treatment under study,
and should be considered in planning for such a trial.
Our goal differs from the objective of a more tra-
ditional trial design approach in that we do not wish to
compare a single new treatment duration to an existing
standard treatment. Instead, we wish to evaluate the ef-
fects of several durations of treatment (d1, d2, . . . ds) on
the cure proportion C. We propose selection of varying
treatment durations that range from the shortest to the
longest duration that provides clinical equipoise. The
total study sample (N) would then be randomized into
strata (s) equal to the number of treatment durations,
and each stratum would then have N1 = N2 = Ns number
of subjects. Thus, the trial would yield s proportions,
where C1, C2, . . . Cs represent the cure proportions in
each individual stratum associated with that stratum-
specific duration of treatment d1 to ds.
Dividing the population into smaller groups yields an
opportunity to gather information about different treat-
ment durations simultaneously. However, the cost of this
opportunity is the loss of some of the statistical preci-
sion of the cure proportion observed in each stratum,
resulting in larger CIs around the point estimates
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what would have been achieved if all subjects had been
in a single stratum and allocated to a single treatment
duration. We propose that this loss of statistical preci-
sion can be mitigated by utilizing the relationship be-
tween treatment duration and cure proportion in a
statistical model, thus giving information about the rela-
tionship between Ci and di for a range of i rather than
just estimating Ci for one duration di. The following lo-
gistic regression model can be used to relate the duration






where Pij is the probability of a cure in patient j in duration
group i, and di is the duration of treatment for duration
group i. The parameters in this logistic regression model
can be related to various quantities of interest for the trial.
The parameter α corresponds to the log odds of a cure
without treatment, and the parameter γ corresponds to
the log odds ratio for a cure corresponding to an increase
in the duration of the new treatment by one unit. While
this logistic regression model uses the postulated linear re-
lationship between treatment duration and the log odds of
a cure, the model could be changed to reflect other forms
for this relationship as needed.Figure 1 Comparison of cure proportions and 95% CIs obtained from
regression model of proposed trial design with 100 subjects per arm
cure proportion is shown on the y-axis. Open boxes and light bars show th
closed circles and dark bars show the point estimates and 95% CIs using th
as in the independent samples. CI, confidence interval.Results
Estimating cure proportion
Estimates derived from fitting this logistic regression
model to the hypothetical trial data allow the calculation
of the predicted probability (and a 95% CI around this
probability) of a cure for selected treatment durations
taking into account the estimate of the cure proportion
at each of the other treatment durations included in
the model. The statistical advantage of this modeling
approach is that although the sample size in each indi-
vidual stratum has been made smaller, the estimate of
the cure proportion will be made more precise by using
information from the other strata, assuming that the
specified model is acceptable. Figure 1 demonstrates
this by showing: a. the cure proportion and 95% CI for a
hypothetical sample of 100 subjects calculated for each
of seven selected treatment durations without consider-
ation of the other strata; and b. the cure proportion and
95% CI for a hypothetical sample of 100 subjects calcu-
lated for each of seven treatment durations including
the other strata using logistic regression as described
above.
Use of the logistic regression model in conjunction with a
control arm to establish non-inferiority
Standard treatment regimens already exist for many
diseases. We therefore propose an extension of our
approach to include comparison of multiple durations ofconventional trial design with 100 subjects per arm and logistic
. The number of weeks of treatment is shown on the x-axis, while the
e point estimate and 95% CI using independent samples, while the
e proposed regression model and the same number of study subjects
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¼ αþ βþ γdið Þzij
where Pij is the probability of a cure in patient j in duration
group i, di is the centered duration of treatment for dur-
ation group i, and zij is an indicator term for type of treat-
ment; the treatment indicator will be equal to 0 for
subjects who receive the standard regimen and equal to 1
for subjects who receive any duration of the new regimen.
The parameter α corresponds to the log odds of a cure on
the standard regimen. The parameter β is the log odds ra-
tio comparing the cure proportion of the new regimen
when di is equal to 0 to that of the standard regimen. We
center the values of di at 0 to make β a useful quantity to
estimate, which would otherwise be a necessary, but not
interpretable, intercept. Finally, the parameter γ corre-
sponds to the log odds ratio for a cure corresponding to
an increase in the duration of the new regimen by one
unit. In this model, the odds ratio of a cure comparing any
duration group to the standard regimen is exp(β + γdi)
where di is the centered duration value for the group. As
above, this logistic regression model could be changed to
reflect non-linear relationships between treatment dura-
tions and the log odds of a cure.
Simulation studies
The following is an example of the application of our
proposed trial design to a hypothetical clinical trial of
non-inferiority whose aim is to identify the shortest dur-
ation for tuberculosis antibiotic therapy using new Regi-
men A that is not inferior to treatment with the current
standard regimen. We hypothesize, based on results
obtained from animal models and the observed efficacy of
Regimen A of killing Mycobacterium tuberculosis in vitro,
that durations as short as 14 weeks and as long as 26
weeks could achieve the desired cure proportion, and thus
the shortest effective regimen would lie somewhere be-
tween these two durations.
A conventional trial might allocate 700 subjects to a
standard regimen and 700 subjects to 20 weeks of the
experimental treatment, Regimen A. In the proposed
trial design, instead of allocating all 700 subjects who re-
ceive Regimen A to a single treatment duration, we elect
to distribute the 700 subjects as follows: 100 subjects
each will receive treatment with Regimen A for 14, 16,
18, 20, 22, 24 and 26 weeks. To compare this to the con-
ventional trial design, we use simulated data to see how
the two designs perform under repeated realizations of
the data that might be generated under ideal conditions.
In particular, we focus on the proportion of simulated
trials under each design that are able to successfullydetermine the non-inferiority of Regimen A at 20 weeks’
duration to the standard regimen.
To simulate the data for these ideal trials, we use the
proposed logistic regression model including a standard
regimen arm with the following parameter values: α = 2.2,
β = 0 and γ = 0.136. These values were chosen to provide
the cure proportions listed in Table 1. The data for 10,000
trials were randomly generated for both the conventional
and proposed trial designs.
To determine the non-inferiority boundary on the
odds scale, we first considered a possible non-inferiority
margin for the difference in proportions. If the cure pro-
portion in the control regimen was 0.90, one might con-
sider a cure proportion of 0.85 to be reasonable for a
shorter treatment regimen, resulting in a non-inferiority
margin of the difference of the cure proportions equal to
0.05. This corresponds to an odds ratio of 0.63 as the mar-
gin of non-inferiority. For this example, non-inferiority
would be demonstrated if the lower bound of the 95% CI
around the odds ratio estimate comparing a given duration
of Regimen A to the standard regimen is greater than 0.63.
To provide odds ratio estimates and 95% CIs for the
simulated trials we used the LOGISTIC Procedure in
SAS (SAS Institute, Cary, NC, USA). In analyses of the
proposed trial design the centered duration (di) was in-
cluded as a linear predictor, allowing the proportion of
Regimen A subjects responding at each of the seven du-
rations to influence the width of the CI for all of the
odds ratios comparing Regimen A to the standard regi-
men. Subjects on the standard regimen had their value
of di set to 0, and there was no duration included in the
logistic regression model for the standard trial design.
Figure 2 shows the results of applying the proposed
logistic regression model to data generated in a single
simulated trial using the proposed trial design. The odds
ratios comparing each treatment duration of Regimen A
to the standard regimen are plotted along with upper
and lower 95% CI bounds. At 20 weeks’ duration, Regi-
men A would be considered to be non-inferior to the
standard regimen as the lower bound of the CI is above
the non-inferiority margin of 0.63. In fact, in this particu-
lar simulated dataset, all Regimen A treatment durations
of 18 weeks or longer would be judged to be non-inferior
to the control.
The results from the simulations are shown in Table 2.
This table gives average values across the 10,000 simula-
tions of the predicted cure proportions, log odds of a
cure, and standard error of the log odds for both the
conventional and proposed trial designs by treatment
and duration groups. We see that the standard error of
the predicted log odds values for 20 weeks’ duration of
treatment on Regimen A in the proposed trial is close to
the standard error of the log odds for Regimen A sub-
jects in the conventional trial, despite the fact that in the
Table 1 Cure proportions for 10,000 simulated trials using conventional and proposed trial designs
Trial design and treatment Number of subjects Treatment duration (weeks) Cure proportion
Conventional trial design
Standard regimen 700 NA 0.90
Regimen A 700 14 0.90
Proposed alternative trial design
Standard regimen 700 NA 0.90
Regimen A 100 14 0.80
Regimen A 100 16 0.84
Regimen A 100 18 0.87
Regimen A 100 20 0.90
Regimen A 100 22 0.92
Regimen A 100 24 0.94
Regimen A 100 26 0.95
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treated for 20 weeks and only 100 subjects receive Regi-
men A for exactly 20 weeks in the proposed alternative
trial design; the subjects treated for other durations in
the proposed trial design do provide precision for the
predicted probability (and log odds) of a cure at 20
weeks. Table 3 presents the proportion of simulations
where non-inferiority was reached in comparing the 20
week duration of Regimen A to the standard treatment.
The proportion of simulated trials that achieve non-
inferiority is 73.4% in the conventional trial design, which is
approximately the same as in the proposed alternative trial
design, 72.4% (P = 0.62, χ2 test for independence). However,
the proposed design provides substantial additional infor-
mation about other durations of treatment on Regimen A.Figure 2 Logistic regression estimates of odds ratios for a cure on Re
treatment with Regimen A in a single simulated trial using the propo
connected with the solid line, while the upper and lower 95% CI bounds f
lines. The non-inferiority boundary of 0.63 is shown by the horizontal line a
log scale. CI, confidence interval.To investigate the role of linearity of duration effect
on the design efficiency, we applied the same logistic
model to data simulated so that the effect of duration on
the log odds of a cure was not linear. To keep the range
of cure proportions reasonable, the simulations were set
so that the cure proportions matched those of the previ-
ous at the extremes provided by weeks 14 and 26 (Table 1).
In addition, to prevent biasing the comparisons, the cure
rate at week 20 was kept the same as for the standard
treatment and the symmetry in the log odds around week
20 was maintained. Log odds values for these new simula-
tions were generated using step functions, and cubic and
cube-root polynomials. The simulation using a step func-
tion placing most of the log odds at the extreme values
(cure proportions of 0.8 for all durations less than 20gimen A compared to standard regimen by duration of
sed trial design. Odds ratio estimates are shown by the solid circles
or these estimates are shown with solid circles connected by dashed
t that level on the vertical axis. The vertical axis is presented on the
Table 2 Predicted cure proportion, log odds and standard error of the log odds by trial type, treatment regimen and
duration (average values across the 10,000 simulations)
Trial type and regimen Duration in weeks Average cure proportion Average log odds of cure Standard deviation of log odds of cure
Conventional trial design
Standard regimen 0.900 2.206 0.128
Regimen A 20 0.900 2.207 0.128
Proposed trial design
Standard regimen 0.900 2.207 0.128
Regimen A 14 0.799 1.390 0.190
Regimen A 16 0.840 1.665 0.146
Regimen A 18 0.874 1.939 0.125
Regimen A 20 0.901 2.214 0.136
Regimen A 22 0.922 2.488 0.174
Regimen A 24 0.939 2.763 0.225
Regimen A 26 0.953 3.037 0.283
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than 20 weeks) provided the worst results for the logistic
regression model. In this simulation non-inferiority for the
20 week duration was attained in 64% of the datasets as
opposed to the 72.4% when data were simulated as in
Table 1. The other simulations with non-linear log odds
values had non-inferiority at week 20 attained for between
69% and 72% of the simulated data sets.
It should be noted that equal allocation of subjects to
the standard regimen group and the combined Regimen A
treatment groups (as was done in these simulations) may
not provide the most power to show non-inferiority.
However, varying the allocation ratio between the standard
arm and the seven experimental treatment duration arms
did not provide greater power to reach non-inferiority.
Varying the fraction of subjects allocated to the standard
arm from 40% to 60% resulted in power values between
70.6% and 73.3% in such simulations. The standard arm
proportion had to be substantially more extreme to reduce
the power to a considerable extent: if 980 subjects (70%)
were allocated to the standard arm and the remaining 420
subjects split into the seven treatment groups, power de-
creased to 65.5%, with similar results obtained from put-
ting 30% of subjects into the standard arm. Although we
have not pursued this, there may in some cases be benefit
in considering the effect on power of varying the number
of patients allocated to the different duration groups.
The proposed method of estimating a point estimate of
the cure proportion and the CI around that estimate can
be applied to clinical trials to determine non-inferiority of
regimens of varying durations to an existing standard
course of therapy. In the tuberculosis example, a stan-
dard arm consisting of the World Health Organization
recommended 6-month tuberculosis treatment regimen
would be compared to a single regimen of new drugs,
given for several durations. The SAS code used for thepower simulations in this section may be obtained from
the authors by request.
Application of proposed model to superiority
comparisons
The proposed design could also be used with ran-
domization to a placebo arm to evaluate new drugs for
prevention of tuberculosis disease among infected
contacts of persons with multiple-drug-resistant tuber-
culosis, since no effective treatment currently exists for
this condition. Study of a single duration of a new agent
that was relatively certain to be successful for this indica-
tion would mean that a superiority design could only be
employed until a single effective regimen (likely longer
than optimal) was identified. After this first successful
single-duration trial, all subsequent trials would then need
to be non-inferiority studies, greatly increasing the cost
and time to identification of the optimal regimen. Instead,
we propose studying smaller numbers of subjects random-
ized to several durations, so that the shortest duration that
was superior to placebo could be determined.
Discussion
In this paper, we used the example of tuberculosis to
propose an alternative clinical trial design to evaluate
varying durations of antibiotic treatment, with the
objective of identifying the shortest effective treatment
regimen. In the early days of tuberculosis chemotherapy,
the Medical Research Council (UK) performed sequen-
tial clinical trials to identify the optimal duration of
tuberculosis treatment. These trials succeeded in grad-
ually shortening the duration of therapy from 18 to 6
months [4]. However, the process took place over a 30-
year period and was complicated by the need to explain
why the same regimen could have different performance
characteristics in different geographic regions. Most of
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conclusions were reached when data accumulated over a
long period of time became compelling. In the current
situation, where large multi-site randomized clinical trials
have the potential to enroll many patients and answer
study questions expeditiously, such an iterative approach
is not in the best interests of patients or the medical com-
munity. In addition, with several new anti-tuberculosis
agents potentially becoming available for study within a
few years of one another, the complexity of investigating
different durations of each regimen could quickly exhaust
both the number of patients and the resources available
for such studies.
The proposed analytic strategy could also be applied
to investigating the minimal duration of treatment of
conditions where current treatment is prolonged and ef-
ficacious, but few shorter regimens have been examined,
such as endocarditis and osteomyelitis. The impetus for
such trials is likely to come from the need to minimize
the cost of prolonged treatment, but there are additional
benefits to be gained, such as reduction in unintended
generation of resistance by continuation of antibiotics
for longer durations than necessary. Such risks may be
mediated by selection of antibiotic resistance in host or-
ganisms other than those that are the primary targets of
the antibiotic course (such as commensal gut flora), and
thus may be difficult to measure. In settings such as
tuberculosis, where resistance is largely generated by
antibiotic pressure, it may be possible to measure gener-
ation of antibiotic resistance directly, and this could be
the primary endpoint of a clinical trial using the type of
design outlined here.
The strategy that we describe is analogous to that used
to optimize dose–response relationships in phase 1 and
phase 2 clinical trials [10]. In such trials, several different
doses are studied and the results are modeled to identify
the dose that maximizes efficacy with acceptable toxicity.
In the current study, we assess several different dura-
tions and model the results to identify the duration that
maximizes efficacy without unnecessarily prolonging
duration. To our knowledge, use of this type of modeling
has not been previously described in analyzing results of
phase 3 clinical trials. The example that we have given is
simple and is meant to demonstrate the concept that sim-
ultaneous examination of multiple durations of a single
regimen combined with multivariate logistic regression
modeling will allow more efficient determination of the op-
timal duration of treatment. In addition, the results gener-
ated can be adjusted to account for measured confounders
and imbalances in randomization.
The analytic approach that we have described has sev-
eral limitations. First, there is a cost in precision associ-
ated with studying several durations simultaneously.
However, unless there is strong a priori information todirect selection of the optimal treatment duration, study
of a single duration carries substantial risk that the dur-
ation will be too brief, and thus not reach the cure
target, or too long, establishing a regimen that exposes
patients to excess antibiotic and increases the risk of
emergence of antibiotic resistance. The method that we
have proposed allows efficient use of patient popula-
tions to allow studies to determine the optimal duration
of therapy without a series of sequential trials, each re-
quiring its own control group. Moreover, there is min-
imal increase in sample size required to define the
optimal duration, since information from each duration
contributes to the optimization. Second, like any model-
based approach, our analytic strategy could yield biased
results if the relationship between duration and the out-
come specified in the logistic regression model for the
analysis did not reflect the true relationship. This implies
that the relationship between duration and the outcome
should be carefully considered prior to the trial, and
should be pre-specified in the trial protocol. Since we ex-
pect to be examining durations that are near the optimally
effective duration, we anticipate that the longest durations
studied do not provide additional benefit, whereas the
shortest ones studied will be slightly suboptimal. Thus,
the slope of the regression line can be expected to be near
the top of the duration-response curve and could reason-
ably be modeled as exponential, or linear on the log scale.
Moreover, if this were the case, one could pre-specify use
of a linear trend between the log of duration and the log
odds of the outcome by replacing the duration di with the
log of di. Our simulations of possible scenarios where the
duration effect was not linear revealed that the method
still achieved interpretable results, albeit with some loss of
power. Third, the logistic model estimates do depend on
adequate counts of events in the different duration of
treatment groups, so we would not recommend creating
too many duration groups for the experimental treatment.
Lastly, we were unable to find existing data from clinical
trials that examined different durations of treatment with
which to validate our proposed strategy. We invite any-
one with access to such data to collaborate with us in
such an effort.
Conclusion
In conclusion, we propose that duration-randomized trials
such as this be considered as a practical way to address the
urgent need to develop shortened treatment regimens for
tuberculosis. Using pairwise comparisons between many
different duration groups can, with large enough samples,
identify which of the durations employed in the study
produced the highest proportion cured, but this approach
does not allow one to say anything about durations
not employed in the study. In contrast, the regression
approach, at the price of some assumptions about the form
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directly estimate the shortest duration that would produce
the best proportion cured, even if that exact duration were
not included as one of the groups in the study. It also al-
lows evaluation of the trade-offs between duration of treat-
ment and the proportion of subjects cured. Application of
this analytic strategy to clinical trials of antibiotic therapy
for other infectious diseases could facilitate decreased anti-
biotic usage, thereby reducing cost, minimizing toxicity and
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